about
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the fieldActivating CBL mutations are associated with a distinct MDS/MPN phenotype.Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.KIT D816V and JAK2 V617F mutations are seen recurrently in hypereosinophilia of unknown significance.ICON: Eosinophil DisordersHepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity.Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2).Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia.Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers.The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm.Globular intracytoplasmic inclusions in a patient with chronic lymphocytic leukaemia.Mast cell sarcoma mimicking metastatic colon carcinoma.Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes.Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.Deferasirox in MDS patients with transfusion-caused iron overload--a phase-II study.Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.Comprehensive mutational profiling in advanced systemic mastocytosis.Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms.Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis.Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with Hypereosinophilia.Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2-PDGFRA fusion gene.Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.Diagnostic challenges in the work up of hypereosinophilia: pitfalls in bone marrow core biopsy interpretation.Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene.The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.Fine needle aspiration and core needle biopsy in the diagnosis of lymphadenopathy of unknown aetiology.Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.The soluble transferrin receptor in dysplastic erythropoiesis in myelodysplastic syndrome
P50
Q27003331-2D4B6460-ECF4-4308-A5DB-B3101CE3DEFDQ33403530-3C02C8A5-92A7-4C71-882C-5EE7BC7017B8Q33829070-479C2994-C76D-4487-9A8E-4100D86AE08EQ33881297-44D09346-5B2D-4190-A3C9-F6F345EAAC49Q34195440-6CC69F0F-6B64-4151-9689-73A674318EB5Q34478126-E891FEF4-8427-4004-95DB-B0E6FC064C75Q36834826-1D9846ED-5071-4ED7-89C3-8D79B1286395Q37760706-D96D6495-9EA6-4B63-B5E7-37F76B98AB16Q38453348-5E916622-5FB6-4FCC-921D-AA6A41E64735Q39013004-8EFCD310-6E97-40FD-B087-8FBD17556DDBQ39705938-C627F849-FBA2-4074-854B-1D9E4889C923Q40115606-0E45B9CC-CABF-420A-B0BB-E405112D0EFBQ40171279-EDDEB9FE-4B8C-4790-BDBD-C67DAEBCE721Q40235742-1D01E1A4-9783-4F4D-9E5C-A974A470981DQ42234623-EF440BD0-F4F7-46F4-8A40-AA0FAAD08377Q44769226-53531F96-6755-484A-A64E-E0CE58F71322Q45024814-A6BF005E-C22B-4CBD-B018-15415884DCD0Q45062950-5334E103-02C1-4602-99F6-2CB809ABD238Q46298036-8A714D68-7D8A-4DE3-8C4A-D6505418E832Q46402488-20315C89-2009-47E5-9AB7-8FA925B41F69Q46476524-8FF92846-3CFC-4B07-AABD-4272A64BA0B6Q46716443-4ABE9821-A054-4922-9C99-D1862EFD4BE6Q46849974-C8147895-FF40-450C-B442-D2DF92AEE39BQ47960630-1A825558-D63E-45E0-84D6-644AF5411E44Q48228419-914B1C84-7B3E-4985-AAD3-AF1EF50D4B96Q49381943-D10E452E-FE21-485C-AF78-266DE3BDF7A3Q51795458-871B6DC5-FCDB-4A42-B326-707BD87882BDQ52877857-D6A795FF-52C1-4CEC-89FD-45B4F338DE4BQ52887806-56598DEB-99D2-4F09-8C58-E63482FD3DC6Q53350377-B0218673-B974-46FF-B795-2E2D47C810D7Q53571527-C743BAA2-792C-4EF0-AC4F-B09028078943Q54226486-039CFEDF-3D97-4589-BD9F-F87AE43619E0Q54234141-C17746C2-1C32-4485-A69F-3D1CD7080C39Q54321478-89997242-06BB-4330-AE56-3E6D3A0924E6Q55029786-FEF6629D-99B9-4E38-B0FD-97E0D7F3E977Q59385081-09FD9654-07FF-43D0-862B-5252F9F9C6A1
P50
name
Georgia Metzgeroth
@ast
Georgia Metzgeroth
@en
Georgia Metzgeroth
@nl
type
label
Georgia Metzgeroth
@ast
Georgia Metzgeroth
@en
Georgia Metzgeroth
@nl
prefLabel
Georgia Metzgeroth
@ast
Georgia Metzgeroth
@en
Georgia Metzgeroth
@nl